Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Heidelberg Pharma AG's Revenue for the
three
months ended in May. 2026 was €4.35 Mil. Heidelberg Pharma AG's average Accounts Receivable for the
three
months ended in May. 2026 was €0.10 Mil.
Hence, Heidelberg Pharma AG's Receivables Turnover for the
three
months ended in May. 2026 was 45.26.
Heidelberg Pharma AG (XTER:HPHA) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Heidelberg Pharma AG Receivables Turnover Related Terms
Heidelberg Pharma AG Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Heidelberg Pharma AG's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:HPHA vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Heidelberg Pharma AG's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Heidelberg Pharma AG Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Heidelberg Pharma AG's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Heidelberg Pharma AG (XTER:HPHA) has a Receivables Turnover of 45.26 as of May. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Heidelberg Pharma AG and its competitors. According to the industry distribution chart, Heidelberg Pharma AG ranks #14 out of 842 companies in the Biotechnology industry, placing it in the top 1.7%.
Is Heidelberg Pharma AG's Receivables Turnover too high?
Heidelberg Pharma AG's current Receivables Turnover is 45.26. The Biotechnology industry median Receivables Turnover is 5.27. Heidelberg Pharma AG's value of 45.26 is 759.6% above this industry median. Based on the distribution chart, Heidelberg Pharma AG ranks #14 out of 842 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Heidelberg Pharma AG has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Heidelberg Pharma AG's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Heidelberg Pharma AG ranks #14 out of 842 companies for Receivables Turnover. This places Heidelberg Pharma AG in the top 2% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.27. Heidelberg Pharma AG's value of 45.26 is 759.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Heidelberg Pharma AG's current Receivables Turnover of 45.26 is 759.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Heidelberg Pharma AG and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Heidelberg Pharma AG's current Receivables Turnover is 45.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heidelberg Pharma AG stock overvalued right now?
Based on GuruFocus' analysis, Heidelberg Pharma AG (XTER:HPHA) is currently considered Fairly Valued. The stock's GF Value™ is €2.55, compared to a current price of €2.53 — trading 0.8% below its estimated fair value. The current Receivables Turnover is 45.26 and 759.6% above the Biotechnology industry median of 5.27. Heidelberg Pharma AG's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Heidelberg Pharma AG (XTER:HPHA), the current Receivables Turnover is 45.26 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Heidelberg Pharma AG (XTER:HPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be undervalued.
The current stock price of €2.53 is trading 0.8% below its estimated GF Value™ of €2.55.
GuruFocus considers Heidelberg Pharma AG to be Fairly Valued.
Key valuation signals for XTER:HPHA:
Receivables Turnover: 45.26
GF Value™: €2.55 vs. price of €2.53 (0.8% below fair value)
Industry Position: 759.6% above the Biotechnology median (#14 of 842)
No single metric tells the full story. See the XTER:HPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
51GF Score
Get the complete analysis for XTER:HPHA
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:HPHA has been successfully added to your 
